The UK Cystic Fibrosis Gene Therapy Consortium

Welcome to the UK CFGTC website. Our aim is to develop gene therapy for Cystic Fibrosis (CF).
For more information on Cystic Fibrosis please click here.

 

Multi-Dose Clinical Trial Funding: Latest News 16 March, 2012.

The UKCFGTC is based at three of the UK's leading Universities, Edinburgh, Oxford and Imperial College London.

We are delighted to announce that our grant application to the NIHR EME programme to cover the cost of the Multi-Dose non-viral gene therapy trial in CF patients has been successful.

Multi-Dose Clinical Trial Recruitment

Professor Eric Alton, chief investigator, said: "Our application for EME funding required an intensive effort by many members of the Consortium. It was rigorously peer-reviewed, and our success in being awarded the grant is a strong endorsement of both our non-viral gene therapy programme and the clinical trial design. With funding for this key part of the Consortium's programme secure, we will begin preparations for the trial immediately. We would like to thank the EME board for its confidence in us, and also all of those whose support has reinforced our determination to continue the programme for the benefit of CF patients."

The EME researcher-led programme is funded by the MRC and managed by the NIHR on behalf of the MRC-NIHR partnership.

 

Funding for development of novel viral gene therapy product:

The UKCFGTC is based at three of the UK's leading Universities, Edinburgh, Oxford and Imperial College London. MRC Translational Research Award, Medical Futures Awards, June 2011.

We are also pleased to announce that we have been successful in our bid for funding from the Medical Research Council (DPFS) to develop a novel Lentiviral gene therapy product, specifically designed to target cells in the lung efficiently. In 2011, this new viral product earned two Medical Futures Innovation Awards including Best Therapeutic Innovation in the Respiratory Section, and the MRC Best Translational Research Innovation award.

Principal Investigator Dr Deborah Gill said:  "The Lentiviral work has been a very exciting aspect of our research programme for several years, but the MRC DPFS funding will give us the much needed opportunity to develop our Lentiviral product for Cystic Fibrosis lung disease, moving us closer to our goal of testing this new product in patients".

Regular updates about the forthcoming trial and progress on our research will be posted on this site.

Press releases:

Consortium Press Release

MRC Press Release

Please visit our news page for further news articles.

Research Highlights

Our Clinical Trial Programme

About the Consortium

Site map

 

Home
News
Contact Details
Follow us on Facebook
Events & Fundraising
Careers
Site Feedback
Site Search
The CF Trust

 

Information for Patients on Our Clinical Trial
Latest Clinical Trial News
Contact Details

 

Consortium Members' Internal Website
About Us
How the Consortium Works
Profiles of the Strategy Group
Scientific Advisory Committee
Milestones
Comminuty Review
Oxford University Gene Medicine
Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

 

Our Research
Optimisation of pDNA
Aerosol Delivery
Viral Vectors Development
Assay Development
Core Facilities
Consortium Patents

 

Clinical Programme
GL67A/pGM169
Clinical Team
Tracking Study
The Run-in Study
Single Dose Clinical Trial
Multi Dose Clinical Trial

 

Cystic Fibrosis
What is CF?
History of CF
Discovery of the CFTR Gene
What Causes CF?
CFTR Protein Structure
Cystic Fibrosis Links
Gene Therapy
Introduction to CF Gene Therapy
Why use Gene Therapy for CF?
Other CF Gene Therapy Groups
Examples of Successful Gene Therapy
Gene Therapy Links

 

Publications
Publications in Journals
Conference Posters & Presentations
Book Chapters
Lectures

 

Medical Futures Innovation Award 2011
Introductory Video
What is a Lentivirus
Production of Lentiviruses
Progress to Date
DNAVec
Photo Gallery